Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
NCT07002060
Recruiting
The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years. Study details include: * The study duration will be up to approximately 6 months. * One single dose of the study intervention (vYF or YF-VAX) will be administered subcutaneously at the 1st visit. * The visit(V) frequency will be Day(D) 01 (V01) and D29 (V02). Two telephone calls will be planned at D15 and Month(M)6. N... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
06/16/2025
Locations: Velocity Clinical Research-New Orleans- Site Number : 8400004, New Orleans, Louisiana +3 locations
Conditions: Yellow Fever Immunization
Register for Updates
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160
Recruiting
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
06/16/2025
Locations: GSK Investigational Site, Tucson, Arizona +5 locations
Conditions: Chickenpox
Register for Updates
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824181
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study dur... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
06/13/2025
Locations: The Medici Medical Research- Site Number : 8400008, Hollywood, Florida +15 locations
Conditions: Pneumococcal Immunization
Register for Updates
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
NCT05232851
Active Not Recruiting
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes (locally advanced). PDS0101 is a vaccine made from specific peptides that may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654
Active Not Recruiting
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/13/2025
Locations: Velocity Clinical Research, Phoenix- Site Number : 8400025, Phoenix, Arizona +23 locations
Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Register for Updates
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
NCT06573281
Active Not Recruiting
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/13/2025
Locations: GSK Investigational Site, Rolling Hills Estates, California +8 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
NCT00505063
Completed
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
06/12/2025
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Childhood Cancer, Multiple Diseases
Register for Updates
Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy
NCT05264974
Suspended
The goal of this phase I trial is to evaluate the toxicity and feasibility of a tumor-specific RNA-NP vaccine in patients with stage IIB-IV melanoma who have progressed on anti-PD1 (a-PD1) adjuvant therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/12/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Melanoma
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
NCT06890416
Active Not Recruiting
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/11/2025
Locations: Central Research Associates, Birmingham, Alabama +25 locations
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
NCT06020118
Completed
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
Gender:
ALL
Ages:
Between 6 years and 64 years
Trial Updated:
06/11/2025
Locations: Valleywise Health Comprehensive Health Center, Phoenix, Arizona +7 locations
Conditions: Influenza, COVID-19
Register for Updates
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
06/10/2025
Locations: Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400013, Birmingham, Alabama +49 locations
Conditions: Pneumococcal Immunization
Register for Updates
Combination HTNV and PUUV DNA Vaccine
NCT03718130
Completed
To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
06/09/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Hantaan Virus Disease, Puumala Virus
Register for Updates